Needham has initiated coverage on NewAmsterdam Pharma (NAMS) with a Buy rating and a $36 price target, citing the potential of their cholesterol-lowering drug, obicetrapib. The drug demonstrated significant LDL-C reduction in a Phase 3 trial and could generate blockbuster sales by targeting a large patient population.
The ketogenic diet, while popular for its weight loss benefits, has come under scrutiny for potential health risks. New research reveals it might increase bad cholesterol, disrupt beneficial gut bacteria, and lead to insulin resistance, raising concerns about long-term consequences for heart health, digestion, and diabetes risk.
A slow metabolism can lead to a range of unpleasant symptoms, including weight gain, fatigue, sensitivity to cold, sluggish digestion, and rising cholesterol levels. Nutritionist Karishma Shah highlights these potential effects in a recent Instagram post, emphasizing the importance of maintaining a healthy metabolism for overall well-being.
